Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines
• MD Anderson Cancer Center
Houston, Texas
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
• MD Anderson Cancer Center
Houston, Texas
The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.
• ISCI / University of Miami
Miami, Florida
Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs
• Medical University of South Carolina
Charleston, South Carolina
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells(Rexlemestrocel-L) for the Treatment of Heart Failure.
• Mesoblast Investigational Site 10757 - Cardiology, P.C.
Birmingham, Alabama
• Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital
Birmingham, Alabama
• Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center
Gilbert, Arizona
• (and 56 more...)
Europe
Allogeneic Stem Cell Therapy in Heart Failure
• Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet
Copenhagen Ø, Denmark
• Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet
Copenhagen Ø, Denmark
Stem Cells Therapy in Advanced Heart Failure
• Celestino Sardu
Naples, Italy
• Raffaele Marfella
Naples, Italy
• Celestino Sardu
Napoli, Italy
Stem Cell Therapy in Ischemic Non-treatable Cardiac Disease
• 2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet
Copenhagen, Denmark
Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
• Hospital Universitario Puerta del Mar
Cádiz, Spain
• Hopistal Universitario Reina Sofía
Córdoba, Spain
• Hospital Universitario Virgen de las Nieves
Granada, Spain
• (and 6 more...)
Cell Therapy in HFpEF
• University Medical Center Ljubljana
Ljubljana, Slovenia
Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure
• Zentralklinik Bad Berka
Bad Berka, Germany
• Goethe University Frankfurt
Frankfurt, Germany
• Klinikum Fulda
Fulda, Germany
• (and 3 more...)
Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI
• Polsko-Amerykańskie Kliniki Serca
Ustroń, Poland
Stem Cell Therapy in Non-Ischemic Non-treatable Dilated Cardiomyopathies II: a Pilot Study
• The Heart Centre, Rigshospitalet University Hospital Copenhagen,
Copenhagen, Denmark
Iran
IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients
• Stem Cell and Regenerative Medicine Institute (SCARM)
Tabriz, Islamic Republic of Iran
ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients
• Stem Cell and Regenerative Medicine Institute (SCARM)
Tabriz, Islamic Republic of Iran
China
Treating Heart Failure With hPSC-CMs
• HelpThera
Nanjing, Jiangsu, China
PART II
Type 1 Diabetes
US Studies
China
China/Spain
South America
Canada
Middle East
Sweden
Type 2 Diabetes
US Studies
China
Near East
Vietnam
Other Thoughts
Jeffrey N. Weiss, M.D.
The Healing Institute
Margate, FL
USA
Jeffrey N. Weiss, MD is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology. He entered college at 16 years of age, and medical school at age 19 on full scholarships. While in medical school he obtained a degree in Electrical Engineering, Magna Cum Laude with distinction, and graduated from Medical School, Summa Cum Laude, at 23 years of age.
Dr. Weiss is the author of more than 100 publications, including 11 books, holds more than 20 U.S. and foreign patents, and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc. which have manufactured and sold Dr. Weiss’ inventions worldwide.
Dr. Weiss performed the first retinal stem cell surgery in the world in 2010 and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, The Neurologic Stem Cell Treatment Study, The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study, and The Alzheimer’s, Cognitive Impairment and Autism Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH and listed on ClinicalTrials.gov.
Dr. Weiss first visited Dubai in 2008, where equipment he had invented was being showcased at Arab Health, the second largest medical equipment meeting in the world. In 2015, he obtained a Dubai medical license and has been travelling to Dubai to examine patients, perform surgery and lecture. His work has been featured in all the major Dubai newspapers and television. He was a finalist for the United Arab Emirates HealthCare Award in 2018 and 2019.
This book examines the application of stem cell surgery for diabetes and heart failure.
Organized into two sections, the first identifies and summarizes the current worldwide stem cell trials for heart failure. Subsequent chapters in part two analyze the current worldwide stem cell trials in patients with Diabetes Mellitus. Both sections utilize studies that include non-expanded stem cells; each study is grouped by stem cell type and geographic location.
Stem Cell Surgery Trials in Diabetes and Heart Failure is a comprehensive, convenient reference for cardiologists, endocrinologists, internists, and family physicians.